Earnings Feed
Start Free
Home/Filings/4/0001179110-09-012856
4//SEC Filing

SALDARINI RONALD J 4

Accession 0001179110-09-012856

CIK 0000874255other
View on SEC.govCompany Profile

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 4:00 PM ET

Size

24.5 KB

Accession

0001179110-09-012856

Insider Transaction Report

Form 4
Period: 2009-09-01
MEDAREX INCMEDX
SALDARINI RONALD J
Director
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−18,000$288,000→ 0 total
    Exercise: $3.72Exp: 2019-03-04→ Common Stock (18,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−18,000$288,000→ 0 total
    Exercise: $9.84Exp: 2015-07-25→ Common Stock (18,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−18,000$288,000→ 0 total
    Exercise: $7.91Exp: 2018-05-14→ Common Stock (18,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−14,000$224,000→ 0 total
    Exercise: $5.59Exp: 2013-07-23→ Common Stock (14,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−18,000$288,000→ 0 total
    Exercise: $4.89Exp: 2014-08-10→ Common Stock (18,000 underlying)
  • Disposition to Issuer

    Restricted Stock

    2009-09-01$16.00/sh−6,721$107,536→ 0 total
    → Common Stock (6,721 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−18,000$288,000→ 0 total
    Exercise: $14.92Exp: 2017-05-16→ Common Stock (18,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−14,000$224,000→ 0 total
    Exercise: $7.48Exp: 2012-07-22→ Common Stock (14,000 underlying)
  • Disposition to Issuer

    Restricted Stock

    2009-09-01$16.00/sh−3,161$50,576→ 0 total
    → Common Stock (3,161 underlying)
Footnotes (11)
  • [F1]This option was canceled in the merger in exchange for a cash payment of $19,530.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F10]This restricted stock unit was canceled in the merger in exchange for a cash payment of $107,536.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F11]The restricted stock units vested ratably on each of the first, second and third anniversaries of the grant date and the receipt ofthe shares of common stock was deferred until the individual's retirement or separation of service from the Board.
  • [F2]This option was canceled in the merger in exchange for a cash payment of $110,970.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F3]This option was canceled in the merger in exchange for a cash payment of $145,620.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F4]This option was canceled in the merger in exchange for a cash payment of $119,287.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F5]This option was canceled in the merger in exchange for a cash payment of $145,740.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F6]This option was canceled in the merger in exchange for a cash payment of $200,070.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F7]This option was canceled in the merger in exchange for a cash payment of $221,040.00, representing the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
  • [F8]Each restricted stock unit respresents a contingent right to receive one (1) share of Medarex, Inc. common stock.
  • [F9]This restricted stock unit was canceled in the merger in exchange for a cash payment of $50,576.00, based on the merger consideration ($16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

Documents

1 file

Issuer

MEDAREX INC

CIK 0000874255

→
Entity typeother

Related Parties

1
  • filerCIK 0001246545

Filing Metadata

Form type
4
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 4:00 PM ET
Size
24.5 KB
View on SEC.gov